Showing results (91-100 of 258) with videos related to

Sort By:
Pageof 26
Oncogene|February 16, 2016
Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53X Xie, G Lozano, Z H Siddik
Oncogene|September 1, 1999
Anti-apoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutantP Lassus, C Bertrand, O Zugasti, et al.
Oncogene|April 21, 2001
A monoclonal antibody against DNA binding helix of p53 proteinE Yolcu, B S Sayan, T Yağci, et al.
International Journal of Cancer|June 22, 1995
p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissueC P Wild, M Ridanpää, S Anttila, et al.
Nature Medicine|July 1, 1995
Serum p53 antibodies as early markers of lung cancerR Lubin, G Zalcman, L Bouchet, et al.
Cancer Research|November 15, 1992
The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spotB Schlichtholz, Y Legros, D Gillet, et al.
Molecular and Cellular Biology|June 1, 1993
The tumor suppressor p53 regulates its own transcriptionA Deffie, H Wu, V Reinke, et al.
Cell Death and Differentiation|July 19, 2008
The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survivalY A Valentin-Vega, H Okano, G Lozano
Nucleic Acids Research|February 21, 1998
Databases and software for the analysis of mutations in the human p53 gene, human hprt gene and both the lacI and lacZ gene in transgenic rodentsN F Cariello, G R Douglas, N J Gorelick, et al.
Nucleic Acids Research|January 1, 1997
Databases and software for the analysis of mutations in the human p53 gene, the human hprt gene and both the lacI and lacZ gene in transgenic rodentsN F Cariello, G R Douglas, M J Dycaico, et al.
Pageof 26